venBio is a life sciences venture capital firm founded in 2011 that partners with industry leaders to build game-changing medicines and technologies, focusing on novel therapeutics for unmet medical needs. The firm has raised nearly $2 billion in total committed capital since inception and is currently investing out of its fifth fund of approximately $528 million. venBio takes an active role in portfolio companies, providing strategic guidance across research, clinical, and business activities from early to late stages of clinical development.
57% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $91.4M (across 74 rounds with reported amounts).
Portfolio
52
Fund Size
$528M
Top Stage
Series A
Last 12 Mo
2
Team
Corey Goodman, PhD
Co-founder and Managing Partner
Robert Adelman, MD
Co-founder and Emeritus Managing Partner
Aaron Royston, MD, MBA
Managing Partner
Yvonne Yamanaka, PhD
Partner
Daniel Teichmann
Controller
David Pezeshki, CFA, CPA
Chief Financial Officer
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| PParabilis | Series F | $305M | Sep 2026 |
 Vyne Therapeutics | Unknown | $200M | Jul 2026 |
 Caldera Therapeutics | Series A | $75M | Jan 2026 |
 Artiva Biotherapeutics | Series B | $120M | Jan 2026 |
| PParabilis | Series F | $305M | Jan 2026 |
 35 Pharma | Series C | $53M | Nov 2024 |
 Axonis | Series A | $115M | Oct 2024 |
 Vicebio | Series B | $100M | Sep 2024 |
 Ventyx Biosciences | Series A | $27M | Sep 2024 |
 Alumis | Series C | — | Jun 2024 |
 Attovia Therapeutics | Series B | $105M | May 2024 |
 Aeovian Pharmaceuticals | Unknown | $50M | Mar 2024 |
| Alumis | Series C | $259M | Mar 2024 |
| AAttralus | Series B | $201M | Feb 2024 |
| AAxonis Therapeutics | Series A | $115M | Jan 2024 |
| Axonis | Series A | $115M | Jan 2024 |
 Abdera Therapeutics Inc. | Series B | — | Apr 2023 |
| Abdera Therapeutics Inc. | Series A | $142M | Apr 2023 |
| AAbdera | Series B | $110M | Apr 2023 |
 Abdera Therapeutics | Series B | $110M | Jan 2023 |
 Entact Bio | Series A | $81M | Dec 2022 |
 Entact | Series A | $81M | Dec 2022 |
| AAcelyrin, Inc | Series C | $300M | Sep 2022 |
| IImmPACT Bio USA | Series B | $111M | Jan 2022 |
| Abdera Therapeutics Inc. | Series B | — | Jan 2022 |
Top Co-Investors
Last updated: 20 October 2026